Who
Jeffrey W. Sherman
Director
Company insider
Files Form 4 as: Director, Larimar Therapeutics; Director, Xeris Biopharma Holdings; EVP and Chief Medical Officer, Horizon Therapeutics Public Ltd Co; Director, Strongbridge Biopharma; Director, Xeris Pharmaceuticals; Sr. VP, R & D and CMO, Idm Pharma; Ex. V.P. - Chief Med. Officer, Neopharm.
In numbers
- Trades disclosed
- 248
- Buys
- 3
- Sells
- 20
- Bought
- $65K
- Sold
- $31.6M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 25 Jan 2006
- Last trade
- 19 May 2026
- Last filed
- 20 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 20 May 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,150 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,150 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K5,000 at $5.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | LRMR Larimar TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K5,000 at $5.00 | filing |
| 28 Aug 2025filed 29 Aug 2025 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —47,040 at $0.00 | filing |
| 28 Aug 2025filed 29 Aug 2025 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $313K47,040 at $6.66 | filing |
| 28 Aug 2025filed 29 Aug 2025 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $334K42,232 at $7.92 | filing |
| 4 Jun 2025filed 4 Jun 2025 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 5 Jun 2024filed 5 Jun 2024 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 15 Mar 2024filed 11 Apr 2024 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code J | —6,502 | filing |
| 27 Nov 2023filed 29 Nov 2023 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Bought | $10K5,400 at $1.87 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —164,469 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —9,314 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —12,696 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —18,397 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —12,226 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —4,654 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —27,942 | filing |
News
No headline names them, or the companies they trade most, lately.